Survival outcomes were less favorable regarding response rate, with a 60-day mortality of 26% vs. 4% and overall survival of 5.2 and 19.4 months in TP53-mutated and WT-TP53 AML, respectively [68]. The gene discussed is TP53; the disease is acute myeloid leukemia.